Revance Wins FDA Approval for RHA Redensity Eye Filler
Nashville, Tennessee, August 20, 2026 Revance and Teoxane have announced FDA approval for RHA Redensity® Eye, a hyaluronic acid...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Nashville, Tennessee, August 20, 2026 Revance and Teoxane have announced FDA approval for RHA Redensity® Eye, a hyaluronic acid...
SAN DIEGO, California, July 2, 2026 Circular Genomics has unveiled CircPATH™, its proprietary circular RNA (circRNA) discovery and validation...
ROSEMONT, Illinois, July 2, 2026 The American Academy of Orthopaedic Surgeons (AAOS) has released its first-ever Clinical Practice Guideline...
BARCELONA, Spain, June 17, 2026 Skin Tech Pharma Group has announced that its flagship injectable treatment, RRS® HA LONG...
IRVINE, Calif., April 08, 2026 iHerb Holdings, Inc., a leading global e-commerce platform for health and wellness products, has...
Paris, France, April 7, 2026 Global Contracts Strengthen Aesthetic Market Leadership In a major development for the global aesthetic...
ZUG, Switzerland, January 29, 2026 — Galderma, the global pure-play dermatology leader, has unveiled ‘Wake Up To Restylane®’, a...
Nashville, Tenn., January 13, 2026 — Revance and Teoxane announced that the U.S. Food and Drug Administration has approved...
